Abstrakt
Background: A second cancer is a different type of cancer than the original cancer. It is diagnosed after a completed treatment for the first cancer. Second cancers occur in only one to three percent of survivors. The level of risk is very small. In general, greater numbers of cancer survivors are living longer due to improvements in treatment. Whether or not a second cancer develops is dependent on many factors. These include the age of the patient when treated, the treatment received, the genetic make-up and family history. The actual number of people who will get a second cancer is relatively small. Each cancer survivor’s experience is unique. The aim of this report is to call attention to what might be an emerging place of secondary malignancies in cancer survivors in our setting.
Method: We report a case seen in our practice of a seventy five year old woman who was treated for invasive ductal carcinoma of the left breast and developed invasive endometrial carcinoma about 4 years later.
Conclusion: There is a need to be on the lookout for possible second malignancies in cancer survivors. Examination and tests for second malignancies should be part of the routine follow up procedures in this group of patients.
Keywords: Second malignancy, tamoxifen, breast and endometrial cancer
Résumé
Contexte: Un deuxième cancer est un autre type de cancer que l’original du cancer. Il est diagnostiqué après un traitement terminé pour la première le cancer. Deuxième cancers surviennent dans seulement un à trois pour cent des survivants. Le niveau de risque est très petite. En général, un plus grand nombre de survivants du cancer vivent plus longtemps, en raison des améliorations du traitement. Qu’il s’agisse ou non d’un deuxième cancer développe est tributaire de nombreux facteurs. Cela inclut l’âge du patient lors d’un traitement, le traitement reçu, la génétique et l’histoire familiale. Le nombre réel de personnes qui obtiendront un deuxième cancer est relativement faible. Chaque survivant du cancer l’expérience est unique. L’objectif de ce rapport est d’appeler l’attention sur ce qui pourrait être une nouvelle place de tumeurs malignes secondaires de survivants du cancer.
Méthode: Nous signalerun cas observé dans notre pratique de soixante cinq ans femme qui a été traitée pour invasif carcinome canalaire du gauche breastand envahissantes développés endomètre environ 4 ans plus tard.
Conclusion: Il est nécessaire d’être à l’affût d’éventuelles tumeurs malignes secondaires de survivants du cancer. Examen et essais de tumeurs malignes secondaires devrait faire partie de la routine procédures de suivi dans ce groupe de patients.
Correspoodence: Dr. Abbas A Abdus-Salam, Department of Radiotherapy, College of Medicine, University of Ibadan, Ibadan, Nigeria. E-mail: adusa@gmail.com
Reference
Parkin DM, Bray F, Ferlay J and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001 Oct 15; 94(2):153-156.
Solanke TF. An overview of cancer in Nigeria. In: Solanke TF, Adebamowo CA (eds). Report of a workshop on state ofthe art in oncology in Ibadan and Ife. National Headquarters of Cancer Registries in Nigeria, Ibadan (1996), 7-12.
Perez CA. and Taylor ME. ‘Breast: Stage Tis, T1 and T2 tumours’, in Perez, C.A. and Brady, L.W. (Eds.): Principles and Practice of Radiation Oncology, 3rd ed.Lippincott - Raven Publishers, Philadelphia, 1998; pp.1269-1415.
Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR). Cancer in Australia: an overview, 2010. Canberra: AIHW .Cancer series no. 60. Cat. no. CAN 56.
Ketiku KK .The pattern of metastasis in Nigeria breast cancer patients. Clinical oncology.1986; 37:563-565.
Adebamowo CA and Ajayi OO. Breast cancer in Nigeria. West Afr J Med. 2000; 19:179–191.
Boice JD Jr, Storm HH, Curtis RE, et al. Multiple primary cancers in Connecticut and Denmark. Monogr Natl Cancer Inst. 1985; 68:1–437. 7.
Ahsan H, Insel BJ and Neugut AI. Risk estimates for second primary cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia (PA): Lippincott Williams and Wilkins; 1999. p. 27–53.
Kamigaki Y and Kawakami K. Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study. Oncology Letters September-October 2011Volume 2 Number 5,Pg: 963-973
Magriples U, Naftolin F, Schartz PE and Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11:485-490
Tayade S and Kumar N. Malignant Mixed Mullerian Tumour of the Uterus– a Complication of Tamoxifen Therapy for Breast Carcinoma. International Journal of Biomedical and Advance Research 2012. Volume:3 Issue:5 pages: 451-454
Fisher B, Joseph P. Costantino, D. et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of the National Cancer Institute, September 16, 1998;Vol. 90, No. 18.
Lasset C, Bonadona V, Mignotte H and Brémond A. Tamoxifen and risk of endometrial cancer. The Lancet, 6 January 2001; Volume 357, Issue 9249, Page 66.
Park CK, Apte S, Acs G and Harris EER. Cancer of the endometrium. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008: chap 92.
Sismondi P, Biglia N, VolpiE, et al.Tamoxifen and endometrialcancer. Ann N Y AcadSci 1994; 734:310-321.
Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project(NSABP) B-14 J. Natl Cancer Inst 1994;86;527-537.
Abudu EK, Musa O, Adefuye PO, et al. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female.A case report and review of the literature. NigerPostgrad Med J 2007 Dec; 14(4):355-357.
Semiglazov VF, Maksimov SI, Bulgatova EA, et al. Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen.VoprOnkol. 2003; 49(2):198-204.
Boice JD Jr, Harvey EB, Blettner M. et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992; 326:781–785.